Skip to main content
SpringerLink
Log in

Newer drugs for asthma

  • Symposium on Pulmonology
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Several new drugs have resulted from innovative pharmacological and immunomodulatory approaches towards treatment of asthma. Diverse therapeutic targets have provided new agents. The new classes of drugs available are newer “on site activated inhaled corticisteroids” and soft steroids, anti IgE compounds, leukotriene inhibitors and single isomer agents which are available for clinical use. Anti interleukin agents and phosphodiesterase inhibitors are in the stage of clinical trials. Antisense therapy and pharmacogenetics are the on horizon for treatment of asthma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National Heart Lung and Bloood Institute, Expert Panel Report Guidelines for the diagnosis and management of asthma. National Institutes of Health, Bathesda HD, 1997 Publication No. 95-3659.

  2. Dahl R, Nielson LP, Christensen MB, Engelstatter R. Ciclesonide-an inhaled corticosteroid prodrug inhibits allergen induced early and late phase reactions.Eur Respir J 1998; 28: 62.

    Google Scholar 

  3. Bodor N, Buchwald P. Soft drug design. General principles and recent applications.Med Res Rev 2000; 20: 58–101.

    Article  PubMed  CAS  Google Scholar 

  4. Bennich HH, Ishizaka K, Johansson SGOel al. Immunoglobulin E, a new class of human immunoglobulin.Bull WHO 1968; 38: 151–152.

    Google Scholar 

  5. Burrows B, Martinez FD, Halonen Met al. Association of asthma with serum IgE levels and skin-test reactivity to allergens.N Engl J Med 1989; 320: 271–277.

    Article  PubMed  CAS  Google Scholar 

  6. Sears MR, Burrows B, Flannery EMet al. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children.N Engl J Med 1991; 325: 1067–1071.

    Article  PubMed  CAS  Google Scholar 

  7. Milgrom H, Fick RB, Su JQet al. Treatment of allergic asthma with monoclonal anti-IgE antibody.N Engl J Med 1999; 341: 1966–1973.

    Article  PubMed  CAS  Google Scholar 

  8. Benson M, Strannegard II, Wennergren G, Strannegard O. Cytokines in nasal fluids from school children with seasonal allergic rhinitis.Pedktric Allergy Immunol 1997; 8: 143–149.

    Article  CAS  Google Scholar 

  9. Borish L, Nelson H, Lanz M, Claussen L, Whitmore J, Agosti Jet al. Recombinant human interleukin-4 receptor in moderate astopic asthma: A randomized double-blind, placebocontrolled pilot study.Am J Respir Crit Care Med 1999; 160: 1816–1823.

    PubMed  CAS  Google Scholar 

  10. Leckie MJ, ten Brinke A, Lordan J, Khan J, Diamant Z, Walls CMet al. SB 240563, a humanised anti-IL-5 monoclonal antibody: initial single dose safety and activity in patients with asthma.Am J Respir Crit Care Med 1999; 159: A624.

    Google Scholar 

  11. Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo.J Exp Med 1995; 182: 1169–1174.

    Article  PubMed  CAS  Google Scholar 

  12. Torphy TJ. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents.Am J Respir Crit Care Med 1998; 157: 351–370.

    PubMed  CAS  Google Scholar 

  13. Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, Nieman RB, Compton CH. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic.Pulm Pharmacol Ther 1999; 12: 131–135.

    Article  PubMed  CAS  Google Scholar 

  14. Panettieri RA, Eszterhas A, Cieslinski LB, Torphy TJ. Ariflo® (SB 207499) modulates human airway smooth muscle cell proliferation induced by mitogens.Am J Respir Crit Care Med 2000; 161: A697.

    Google Scholar 

  15. Shrewsbury S, Pyke S, Britton M. A meta-analysis of incresing inhaled steroid or adding salmeterol in symptomatic asthma (MIASMA).BMJ 2000; 320: 1368–1373.

    Article  PubMed  CAS  Google Scholar 

  16. Evans DJ, Taylor DA, Zetterstrom O, Fan Chung K, O’Connor BJ, Barnes PJ. A comparison of low dose inhaled budesonide plus theophylline and high dose inhaled budesonide for moderate asthma.N Engl J Med 1997; 337: 1412–1418.

    Article  PubMed  CAS  Google Scholar 

  17. Wilson AJ, Gibson PG, Coughlan J. Long-acting beta-agonists versus theophylline for maintenance treatment of asthma.Cochmne Database Syst Rev 2000; 1: 1–11.

    Google Scholar 

  18. Lynch KR, O’Neill GP, Liu Q, Im DS, Sawyer N, Metters KM,et al. Characterization of the human cysteinyl leukotriene CysLTI receptor.Nature 1999; 399: 789–793.

    Article  PubMed  CAS  Google Scholar 

  19. Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway.N EnglJ Med 1999; 340: 197–206.

    Article  CAS  Google Scholar 

  20. Gawchik SM, Saccar CL, Noonan M, Raesner DS, DeGraw SS. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients.J Allergy Clin Immunol 1999; 103: 615–621.

    Article  PubMed  CAS  Google Scholar 

  21. Edell D, Perlander F, Khoshoo V. Comparative efficacy of levalbuterol (LA) and racemic albuterol (RA) in infants with reactive airway disease (RAD) using crying vital capacity (CVC) measurements.Ann Allergy Asthma Immunol, (in press).

  22. Nelson HS, Bensch G, Pleskow WW, DiSantostenfano MS, DeGraw S, Reasner DSet al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma.J Allergy Clin Immunol 1998; 102: 943–952.

    Article  PubMed  CAS  Google Scholar 

  23. Truitt TJ, Witko J, Kotter S, Gordon I. Levalbuterol reduces total and breakthrough treatments in hospitalized patients.Am J Respir Crit Care Med 2000; 137: 248S.

    Google Scholar 

  24. Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer C-A, O’Byrne PMet al. Exacerbations of asthma: A descriptive study of 425 severe exacerbations.Am J Respir Crit Care Med 1999; 160: 594–599.

    PubMed  CAS  Google Scholar 

  25. Nyce J. Respirable oligonucleotides: A new, third drug class targeting respiratory disease.Current Opinions in Allergy Clin Immunol 2002; 2 (6): 533–536.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India

    Meenu Singh (Additional Professor of Pediatrics)

Authors
  1. Meenu Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meenu Singh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Singh, M. Newer drugs for asthma. Indian J Pediatr 71, 721–727 (2004). https://doi.org/10.1007/BF02730663

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02730663

Keywords

Search

Navigation